Schematic overview of the cellular and molecular mechanisms involved in the cancer progression, including the proposed cellular and molecular mechanisms in cancer cells trajectory. AT1: alveolar type 1 cells; AT2: alveolar type 2 cells; AAH: atypical adenomatous hyperplasia; AIS: adenocarcinoma in situ; MIA: minimally invasive adenocarcinoma; IA: invasive adenocarcinoma; EMT: epithelial-mesenchymal transition

Home

Download

Statistics

Help

Contact

	Gene summary
	Malignant transformation analysis
	Malignant transformation related pathway analysis
	Cell-cell communication analysis
	Single-cell gene regulatory network inference analysis
	Somatic mutation of malignant transformation related genes
	Related drugs of malignant transformation related genes

Gene: ITCH

Gene summary for ITCH

Gene summary.

Gene information	Species	Human
	Gene symbol	ITCH
	Gene ID	83737
	Gene name	itchy E3 ubiquitin protein ligase
	Gene Alias	ADMFD
	Cytomap	20q11.22
	Gene Type	protein-coding
	GO ID	GO:0000165
	UniProtAcc	Q96J02

Top

Malignant transformation analysis

Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells

Malignant transformation involving gene list.

Entrez ID	Symbol	Replicates	Species	Organ	Tissue	Adj P-value	Log2FC	Malignancy
83737	ITCH	P27T-E	Human	Esophagus	ESCC	5.21e-26	3.93e-01	0.1055
83737	ITCH	P28T-E	Human	Esophagus	ESCC	2.77e-19	3.54e-01	0.1149
83737	ITCH	P30T-E	Human	Esophagus	ESCC	4.56e-27	7.30e-01	0.137
83737	ITCH	P31T-E	Human	Esophagus	ESCC	6.56e-40	6.19e-01	0.1251
83737	ITCH	P32T-E	Human	Esophagus	ESCC	4.86e-52	9.52e-01	0.1666
83737	ITCH	P36T-E	Human	Esophagus	ESCC	3.20e-27	7.00e-01	0.1187
83737	ITCH	P37T-E	Human	Esophagus	ESCC	1.52e-23	4.27e-01	0.1371
83737	ITCH	P38T-E	Human	Esophagus	ESCC	4.96e-10	3.93e-01	0.127
83737	ITCH	P39T-E	Human	Esophagus	ESCC	1.44e-27	4.09e-01	0.0894
83737	ITCH	P40T-E	Human	Esophagus	ESCC	9.88e-11	3.72e-01	0.109
83737	ITCH	P42T-E	Human	Esophagus	ESCC	2.97e-21	4.41e-01	0.1175
83737	ITCH	P44T-E	Human	Esophagus	ESCC	4.26e-12	3.52e-01	0.1096
83737	ITCH	P47T-E	Human	Esophagus	ESCC	4.30e-34	5.81e-01	0.1067
83737	ITCH	P48T-E	Human	Esophagus	ESCC	9.30e-20	3.54e-01	0.0959
83737	ITCH	P49T-E	Human	Esophagus	ESCC	3.51e-18	1.29e+00	0.1768
83737	ITCH	P52T-E	Human	Esophagus	ESCC	2.05e-26	4.98e-01	0.1555
83737	ITCH	P54T-E	Human	Esophagus	ESCC	8.60e-30	6.32e-01	0.0975
83737	ITCH	P56T-E	Human	Esophagus	ESCC	5.05e-10	1.29e+00	0.1613
83737	ITCH	P57T-E	Human	Esophagus	ESCC	2.52e-23	4.46e-01	0.0926
83737	ITCH	P61T-E	Human	Esophagus	ESCC	1.87e-23	4.94e-01	0.099

Page: 1 2 3 4 5 6 7 8 9 10

Transcriptomic changes along malignancy continuum.

Tissue	Expression Dynamics	Abbreviation
Cervix		CC: Cervix cancer
		HSIL_HPV: HPV-infected high-grade squamous intraepithelial lesions
		N_HPV: HPV-infected normal cervix
Colorectum (GSE201348)		FAP: Familial adenomatous polyposis
		CRC: Colorectal cancer
Colorectum (HTA11)		AD: Adenomas
		SER: Sessile serrated lesions
		MSI-H: Microsatellite-high colorectal cancer
		MSS: Microsatellite stable colorectal cancer
Endometrium		AEH: Atypical endometrial hyperplasia
		EEC: Endometrioid Cancer
Esophagus		ESCC: Esophageal squamous cell carcinoma
		HGIN: High-grade intraepithelial neoplasias
		LGIN: Low-grade intraepithelial neoplasias
Liver		HCC: Hepatocellular carcinoma
		NAFLD: Non-alcoholic fatty liver disease
Lung		AAH: Atypical adenomatous hyperplasia
		AIS: Adenocarcinoma in situ
		IAC: Invasive lung adenocarcinoma
		MIA: Minimally invasive adenocarcinoma
Oral Cavity		EOLP: Erosive Oral lichen planus
		LP: leukoplakia
		NEOLP: Non-erosive oral lichen planus
		OSCC: Oral squamous cell carcinoma
Prostate		BPH: Benign Prostatic Hyperplasia
Thyroid		ATC: Anaplastic thyroid cancer
		HT: Hashimoto's thyroiditis
		PTC: Papillary thyroid cancer

∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage.

Top

Malignant transformation related pathway analysis

Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer

Figure of enriched GO biological processes.

Tissue	Disease Stage	Enriched GO biological Processes
Colorectum	AD
Colorectum	SER
Colorectum	MSS
Colorectum	MSI-H
Colorectum	FAP

∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust).

Page: 1 2 3 4 5 6 7 8 9

Enriched GO biological processes.

GO ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	Count
GO:001603210	Cervix	CC	viral process	109/2311	415/18723	5.40e-15	6.46e-12	109
GO:004217610	Cervix	CC	regulation of protein catabolic process	104/2311	391/18723	9.39e-15	9.36e-12	104
GO:001905810	Cervix	CC	viral life cycle	87/2311	317/18723	2.20e-13	1.20e-10	87
GO:004573210	Cervix	CC	positive regulation of protein catabolic process	65/2311	231/18723	7.44e-11	1.39e-08	65
GO:001049810	Cervix	CC	proteasomal protein catabolic process	111/2311	490/18723	8.98e-11	1.58e-08	111
GO:002240710	Cervix	CC	regulation of cell-cell adhesion	103/2311	448/18723	1.78e-10	2.87e-08	103
GO:190332010	Cervix	CC	regulation of protein modification by small protein conjugation or removal	66/2311	242/18723	2.31e-10	3.46e-08	66
GO:000989610	Cervix	CC	positive regulation of catabolic process	109/2311	492/18723	5.26e-10	6.99e-08	109
GO:005212610	Cervix	CC	movement in host environment	52/2311	175/18723	7.03e-10	8.76e-08	52
GO:004440910	Cervix	CC	entry into host	47/2311	151/18723	8.45e-10	1.03e-07	47
GO:005170110	Cervix	CC	biological process involved in interaction with host	57/2311	203/18723	1.18e-09	1.41e-07	57
GO:00421108	Cervix	CC	T cell activation	107/2311	487/18723	1.24e-09	1.46e-07	107
GO:00508638	Cervix	CC	regulation of T cell activation	80/2311	329/18723	1.28e-09	1.47e-07	80
GO:004671810	Cervix	CC	viral entry into host cell	44/2311	144/18723	5.47e-09	5.03e-07	44
GO:004440310	Cervix	CC	biological process involved in symbiotic interaction	71/2311	290/18723	7.94e-09	6.98e-07	71
GO:00071598	Cervix	CC	leukocyte cell-cell adhesion	85/2311	371/18723	8.27e-09	7.07e-07	85
GO:004316110	Cervix	CC	proteasome-mediated ubiquitin-dependent protein catabolic process	91/2311	412/18723	1.65e-08	1.25e-06	91
GO:00071626	Cervix	CC	negative regulation of cell adhesion	72/2311	303/18723	2.36e-08	1.70e-06	72
GO:00026837	Cervix	CC	negative regulation of immune system process	94/2311	434/18723	2.63e-08	1.87e-06	94
GO:19030378	Cervix	CC	regulation of leukocyte cell-cell adhesion	77/2311	336/18723	4.08e-08	2.54e-06	77

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 46 47 48 49 50 51 52 53 54 55 56

Enriched KEGG pathways.

Pathway ID	Tissue	Disease Stage	Description	Gene Ratio	Bg Ratio	pvalue	p.adjust	qvalue	Count
hsa0493218	Cervix	CC	Non-alcoholic fatty liver disease	58/1267	155/8465	3.58e-12	1.05e-10	6.23e-11	58
hsa0412014	Cervix	CC	Ubiquitin mediated proteolysis	49/1267	142/8465	4.26e-09	7.68e-08	4.54e-08	49
hsa0414418	Cervix	CC	Endocytosis	64/1267	251/8465	6.97e-06	6.10e-05	3.61e-05	64
hsa046686	Cervix	CC	TNF signaling pathway	28/1267	114/8465	4.60e-03	1.62e-02	9.59e-03	28
hsa04330	Cervix	CC	Notch signaling pathway	17/1267	62/8465	7.99e-03	2.56e-02	1.51e-02	17
hsa0493219	Cervix	CC	Non-alcoholic fatty liver disease	58/1267	155/8465	3.58e-12	1.05e-10	6.23e-11	58
hsa0412015	Cervix	CC	Ubiquitin mediated proteolysis	49/1267	142/8465	4.26e-09	7.68e-08	4.54e-08	49
hsa0414419	Cervix	CC	Endocytosis	64/1267	251/8465	6.97e-06	6.10e-05	3.61e-05	64
hsa0466813	Cervix	CC	TNF signaling pathway	28/1267	114/8465	4.60e-03	1.62e-02	9.59e-03	28
hsa043301	Cervix	CC	Notch signaling pathway	17/1267	62/8465	7.99e-03	2.56e-02	1.51e-02	17
hsa04932	Colorectum	AD	Non-alcoholic fatty liver disease	90/2092	155/8465	4.83e-19	1.80e-17	1.15e-17	90
hsa04144	Colorectum	AD	Endocytosis	111/2092	251/8465	5.95e-12	1.42e-10	9.08e-11	111
hsa04120	Colorectum	AD	Ubiquitin mediated proteolysis	58/2092	142/8465	1.46e-05	1.53e-04	9.76e-05	58
hsa049321	Colorectum	AD	Non-alcoholic fatty liver disease	90/2092	155/8465	4.83e-19	1.80e-17	1.15e-17	90
hsa041441	Colorectum	AD	Endocytosis	111/2092	251/8465	5.95e-12	1.42e-10	9.08e-11	111
hsa041201	Colorectum	AD	Ubiquitin mediated proteolysis	58/2092	142/8465	1.46e-05	1.53e-04	9.76e-05	58
hsa049324	Colorectum	MSS	Non-alcoholic fatty liver disease	85/1875	155/8465	4.19e-19	1.17e-17	7.17e-18	85
hsa041444	Colorectum	MSS	Endocytosis	102/1875	251/8465	1.85e-11	4.43e-10	2.71e-10	102
hsa041204	Colorectum	MSS	Ubiquitin mediated proteolysis	55/1875	142/8465	5.02e-06	6.00e-05	3.68e-05	55
hsa049325	Colorectum	MSS	Non-alcoholic fatty liver disease	85/1875	155/8465	4.19e-19	1.17e-17	7.17e-18	85

Page: 1 2 3 4 5 6 7 8

Top

Cell-cell communication analysis

Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states

Ligand

Receptor

LRpair

Pathway

Tissue

Disease Stage

Page: 1

Top

Single-cell gene regulatory network inference analysis

Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states

Cell Type

Tissue

Disease Stage

Target Gene

RSS

Regulon Activity

∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression.

Page: 1

Top

Somatic mutation of malignant transformation related genes

Annotation of somatic variants for genes involved in malignant transformation

Hugo Symbol

Variant Class

Variant Classification

dbSNP RS

HGVSc

HGVSp

HGVSp Short

SWISSPROT

BIOTYPE

SIFT

PolyPhen

Tumor Sample Barcode

Tissue

Histology

Sex

Age

Stage

Therapy Types

Drugs

Outcome

ITCH

SNV

Missense_Mutation

c.673G>A

p.Glu225Lys

p.E225K

Q96J02

protein_coding

tolerated(0.51)

benign(0.293)

TCGA-A8-A0A7-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

ITCH

SNV

Missense_Mutation

c.673G>A

p.Glu225Lys

p.E225K

Q96J02

protein_coding

tolerated(0.51)

benign(0.293)

TCGA-AC-A23H-01

Breast

breast invasive carcinoma

Female

>=65

I/II

Unknown

ITCH

SNV

Missense_Mutation

novel

c.1286N>T

p.Ser429Leu

p.S429L

Q96J02

protein_coding

tolerated(0.27)

benign(0.017)

TCGA-BH-A0B6-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

ITCH

SNV

Missense_Mutation

novel

c.2439N>T

p.Trp813Cys

p.W813C

Q96J02

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-E9-A5UO-01

Breast

breast invasive carcinoma

Female

<65

I/II

Unknown

ITCH

SNV

Missense_Mutation

novel

c.2605N>T

p.His869Tyr

p.H869Y

Q96J02

protein_coding

deleterious(0)

probably_damaging(1)

TCGA-WT-AB41-01

Breast

breast invasive carcinoma

Female

<65

I/II

Chemotherapy

taxotere

ITCH

SNV

Missense_Mutation

novel

c.1657N>G

p.Thr553Ala

p.T553A

Q96J02

protein_coding

deleterious(0.04)

benign(0.011)

TCGA-2W-A8YY-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

ITCH

SNV

Missense_Mutation

novel

c.607N>A

p.Gln203Lys

p.Q203K

Q96J02

protein_coding

tolerated(0.95)

benign(0)

TCGA-C5-A7XC-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

ITCH

SNV

Missense_Mutation

novel

c.787N>C

p.Thr263Pro

p.T263P

Q96J02

protein_coding

tolerated(0.25)

probably_damaging(0.998)

TCGA-DS-A7WH-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Chemotherapy

cisplatin

ITCH

SNV

Missense_Mutation

c.2399N>C

p.Arg800Pro

p.R800P

Q96J02

protein_coding

deleterious(0)

probably_damaging(0.987)

TCGA-EA-A3HT-01

Cervix

cervical & endocervical cancer

Female

>=65

I/II

Unknown

ITCH

SNV

Missense_Mutation

c.719N>G

p.Ser240Cys

p.S240C

Q96J02

protein_coding

deleterious(0.04)

probably_damaging(0.998)

TCGA-MA-AA41-01

Cervix

cervical & endocervical cancer

Female

<65

I/II

Unknown

Page: 1 2 3 4 5 6 7 8 9 10

Top

Related drugs of malignant transformation related genes

Identification of chemicals and drugs interact with genes involved in malignant transfromation

(DGIdb 4.0)

Entrez ID

Symbol

Category

Interaction Types

Drug Claim Name

Drug Name

PMIDs

Page: 1